Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Payables (2023 - 2025)

Zenas BioPharma (ZBIO) has 3 years of Payables data on record, last reported at $6.4 million in Q3 2025.

  • For Q3 2025, Payables fell 57.27% year-over-year to $6.4 million; the TTM value through Sep 2025 reached $6.4 million, down 57.27%, while the annual FY2024 figure was $17.1 million, 217.57% up from the prior year.
  • Payables reached $6.4 million in Q3 2025 per ZBIO's latest filing, down from $7.9 million in the prior quarter.
  • Across five years, Payables topped out at $20.0 million in Q1 2025 and bottomed at $5.4 million in Q4 2023.
  • Average Payables over 3 years is $12.0 million, with a median of $11.5 million recorded in 2024.
  • Peak YoY movement for Payables: soared 217.57% in 2024, then crashed 57.27% in 2025.
  • A 3-year view of Payables shows it stood at $5.4 million in 2023, then skyrocketed by 217.57% to $17.1 million in 2024, then crashed by 62.39% to $6.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $6.4 million in Q3 2025, $7.9 million in Q2 2025, and $20.0 million in Q1 2025.